Breaking News, Collaborations & Alliances

Abbvie, Genmab Enter $750M Antibody Alliance

To jointly develop and commercialize three of Genmab's early-stage investigational bispecific antibody product candidates

By: Contract Pharma

Contract Pharma Staff

AbbVie and Genmab have entered a collaboration to jointly develop and commercialize three of Genmab’s early-stage investigational bispecific antibody product candidates, and to research future differentiated antibody therapeutics for cancer. The companies will partner to develop Genmab’s next-gen bispecific antibody programs, epcoritamab (DuoBody®-CD3xCD20), DuoHexaBody®-CD37 and DuoBody-CD3x5T4 leveraging Genmab’s discovery and development expertise and AbbVie’s clinical...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters